Clinical Trial Update: Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

View source ↗

Summary

A clinical trial update from Ohio State University assessing sex-based differences in cardiovascular-kidney-metabolic health outcomes using GLP-1 receptor agoni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Kidney Disease
• Metabolic Syndrome

Drugs mentioned

• GLP-1 receptor agonists
• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: Ohio State University | Conditions: Cardiovascular Kidney Metabolic Syndrome | Status: ACTIVE_NOT_RECRUITING